

해외 바이오의약품 임상 현황 (2021.2.15~2021.2.21)

한국바이오의약품협회, 2021.2.23.
출처: ClinicalTrials.gov

○ 미국 17건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04676087	Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides	Mycosis Fungoides Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Sezary Syndrome	Procedure: Extracorporeal Photopheresis Biological: Mogamulizumab Other: Quality-of-Life Assessment	Emory University	Phase 1 Phase 2	_____
NCT04762875	This Study Tests a New Medicine for Mobilizing Stem Cells so They Can be Collected and Used for Allogeneic Stem Cell Transplant for Treatment of Hematological Malignancies . MGTA-145, the New Medicine, Will be Given With Plerixafor.	Related Donors Donating PBSC to a Family Member Healthy Donors Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome	Biological: MGTA-145 Biological: Plerixafor	Magenta Therapeutics, Inc. National Marrow Donor Program	Phase 2	_____
NCT04758962	A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults	Virus Diseases	Biological: 1 µg CoV2 SAM (LNP) Biological: 3 µg CoV2 SAM (LNP) Biological: 10 µg CoV2 SAM (LNP) Biological: 30 µg CoV2 SAM (LNP)	GlaxoSmithKline	Phase 1	_____
NCT04754100	AGENT-797 in Patients With Relapsed/Refractory Multiple Myeloma	Relapsed/Refractory Multiple Myeloma	Drug: agent-797	Agentus Therapeutics, Inc. Agentus Inc.	Phase 1	_____
NCT04678336	CD123 Redirected T Cells for AML in Pediatric Subjects	Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, Refractory	Biological: CART123 cells; cyclophosphamide; fludarabine	University of Pennsylvania	Phase 1	_____
NCT04673942	A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors	Solid Tumor, Adult Cancer Neoplasms	Biological: AdAPT-001	EpicentRx, Inc.	Phase 1	_____
NCT04664738	PEP on a Skin Graft Donor Site Wound	Skin Graft	Biological: 10% PEP Drug: TISSEEL Biological: 20% PEP	Steven L. Moran Mayo Clinic	Phase 1	_____
NCT04661384	Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma	Leptomeningeal Metastases	Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	_____
NCT04626583	Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells	Mesenchymal Stromal Cells Cornea Safety Corneal Defect	Biological: Allogeneic MSC	University of Illinois at Chicago United States Department of Defense	Phase 1	_____
NCT04588038	NT-17 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Resectable Oropharyngeal Squamous Cell Carcinoma	Biological: Efinetakin alfa	Hyunseok Kang, MD NeolImmuneTech University of California, San Francisco	Phase 1	_____
NCT04442581	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer	Advanced Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma	Drug: Cabozantinib S-malate Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI) Exelixis	Phase 2	_____
NCT04174560	Phase I Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	_____
NCT04502082	Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)	Hepatocellular Carcinoma Liver Cancer Liver Neoplasm Metastatic Liver Cancer	Biological: ET140203 autologous T cell product	Eureka Therapeutics Inc.	Phase 1 Phase 2	_____
NCT04754594	Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older	SARS-CoV-2 Infection COVID-19 Maternal Immunization	Biological: BNT162b2 Other: Placebo	BioNTech SE Pfizer	Phase 2 Phase 3	_____
NCT04581785	Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia	Methylmalonic Acidemia	Biological: hLB-001	LogicBio Therapeutics, Inc.	Phase 1 Phase 2	_____
NCT04713553	A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 Against COVID-19 in Healthy Participants	SARS-CoV-2 Infection COVID-19	Biological: BNT162b2	BioNTech SE Pfizer	Phase 3	_____
NCT04761770	Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders	Myelodysplastic Syndrome Myeloproliferative Neoplasms Chronic Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Myelodysplastic/Myeloproliferative Overlapping Syndrome	Other: Geriatric assessment (GA) pre-transplant Drug: conditioning regimen Procedure: Allogeneic CD34+ selected stem cells	Memorial Sloan Kettering Cancer Center	Phase 2	_____

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04736134	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants	Healthy Participants	Biological: BMS-986326 Other: Placebo matching BMS-986326	Bristol-Myers Squibb	Phase 1	_____

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04712110	A Study of TAK-019 in Healthy Japanese Adults (COVID-19)	Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)	Biological: TAK-019 Biological: Placebo	Takeda	Phase 1 Phase 2	_____
NCT04683029	A Study of Guselkumab in Participants With Systemic Sclerosis	Scleroderma, Systemic	Drug: Guselkumab Dose 1 Drug: Guselkumab Dose 2 Drug: Placebo	Janssen Pharmaceutical K.K.	Phase 2	_____
NCT04687137	Japan Expanded Access Program With Lanadelumab for Japanese Patients With Hereditary Angioedema	Hereditary Angioedema	Drug: TAK-743 300 mg	Takeda	Phase 3	_____